Several factors argue against assay interference: Obicetrapib’s effects differed across APOE subgroups, with the strongest impact seen in E4/E4 carriers, the group at the highest AD risk with the most pronounced lipid abnormalities. Here, APOE is linked to Alzheimer disease.